We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement
Analytical Cannabis Logo
×

Home > News > Science & Health

A Quarter of Parkinson’s Patients Have Tried Medical Cannabis, but It Doesn’t Always Work, Study Finds

Mar 24, 2021 | by Ben Hartman

A Quarter of Parkinson’s Patients Have Tried Medical Cannabis, but It Doesn’t Always Work, Study Finds

This article was originally published on the Cannigma and appears here with permission.


The majority of people with Parkinson’s disease in the United States have not used cannabis to treat their symptoms due to a lack of scientific evidence about its effectiveness. Of those who have used cannabis, most did not receive a recommendation from a doctor or instructions on how to use it, according to the findings of a recent study. 

Published in Nature Partner Journals and sponsored by the Parkinson’s Foundation, the study found that nearly 25 percent of Parkinson’s patients had used cannabis in the past six months, but that one in four of that group did not know what type or form of cannabis they used, and nearly half did not know their dosage. 

Taken together, the lack of guidance and lack of information about what treatments patients are taking, may underlie “inconsistencies in both use and reported effectiveness,” the researchers stated.

Here are the most interesting statistics from the survey.


Where do Parkinson’s patients get information about cannabis?

Of the respondents who used cannabis:

  • 64 percent said they had not received a recommendation from a healthcare provider.
  • 56 percent had received no information or recommendations about using cannabis.

Of the 43.9 percent who did receive some guidance…

  • 22 percent received it from dispensary staff.
  • 22 percent from friends.
  • 25 percent from a doctor.


Why don’t more patients try cannabis?

Of those who have not used cannabis:

  • 60 percent cited a lack of scientific evidence of its efficacy.
  • 35 percent said the fear of side effects was their main concern.
  • 14 percent cited stigma towards cannabis.
  • 7 percent said they were dismayed by concerns about legality.

What would be a decisive factor if they were to try medical cannabis?

  • 76 percent want more evidence supporting cannabis use for Parkinson’s.
  • 55 percent would want a recommendation from their health care provider.
  • 35 percent said a better understanding of side effects would be of greatest relevance.


How does cannabis help Parkinson’s patients?

  • 41 percent said cannabis somewhat addressed motor symptoms (43 percent for stiffness and 42 percent for tremors)
  • 43 percent said cannabis somewhat addressed non-motor symptoms (46 percent for anxiety, 44 percent for sleep disorders, 44 percent for pain)

Those who use high THC products were 7.43 times more likely to report side effects than those who use high or pure CBD products.

An overwhelming 84.7 percent said that cannabis use had no impact on prescription medication usage, and 89 percent said they had not thought that cannabis would replace their prescription medications for Parkinson’s disease.

The study was compiled by way of an anonymous email survey sent to 7,607 people with Parkinson’s disease in January 2020.

The researchers received 1,339 responses from people in 49 states, with a mean age of 71 years. Altogether, 24.5 percent of respondents said that they had used cannabis in the previous six months, and those who used cannabis were more likely to report that prescription medications provided insufficient control of their non-motor symptoms.

The survey found that nearly a quarter of the cannabis users had stopped using cannabis in the previous six months. Asked why, 35.5 percent of that group said it was because cannabis did not improve their symptoms.

“If cannabis is intended to be used as a medicinal or CAIM (complementary and integrative medicine) treatment for PD, formal recommendations are needed to fill the current knowledge gap around cannabis type, dosage, and efficacy,” the researchers wrote. 

“Any future research or clinical trials targeting the efficacy of cannabis should clearly define these recommendations for use and prioritize the communication of such recommendations to enrolled participants,” they added.

Many of the plant-based cannabinoids in cannabis show potential in treating nervous system disorders, including Parkinson’s Disease, by way of how they interact with the receptors of the body’s endocannabinoid system

A survey carried out in 2018 found that 46 percent of respondents experienced mild to substantial improvement of symptoms, while a much more recent survey carried out in Germany earlier this year found that 54 percent of PD patients who used cannabis said it had a beneficial clinical effect on their condition. 

 

Like what you just read? You can find similar content on the topic tag shown below.

Science & Health

Stay connected with the latest news in cannabis extraction, science and testing

Get the latest news with the FREE weekly Analytical Cannabis newsletter

Comments
 
Advertisement